At Center for Breakthrough Medicines, our mission is to save lives by accelerating the development and manufacturing of advanced therapies.
Our fully integrated services include drug substance and drug product for all phases of the product lifecycle at a single site.
The Center for Breakthrough Medicines (CBM), announced today the launch of their Analytical AcceleratorTM for AAV Testing to help gene therapy developers meet the quality domains of identity, safety, purity, potency, and stability required by the Food and Drug Administration (FDA) and global regulatory authorities.October 19, 2022
Center for Breakthrough Medicines and jCyte Announce Strategic Partnership to Manufacture jCyte’s Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases.September 20, 2022
CBM has appointed of Mandy Conver as Senior Vice President (SVP) of Business Development for Testing & Analytics, and Jennifer Manning as (SVP) of Global Strategic Partnerships.July 27, 2022
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.June 13, 2022
iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM will produce and supply Good Manufacturing Practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE’s future clinical studies to enable development of iECURE’s programs.May 25, 2022
Our empowering culture supports people committed to transforming patients’ lives.Learn More >
CBM is led by an amazing team. Discover the caliber of people you will work with.Learn more >